Metraipolis › archive › dc_a54b2dd9bf5f
Patient-Reported Outcomes After Treatment With OnabotulinumtoxinA for Platysma Prominence: Results From a Phase 2 Dose-Ranging Study — Europe PMC PMID:41933889
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41933889
- DOI
- 10.1111/jocd.70821
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-03T13:00:23.195Z
- SHA-256 of the archived text
c0371134de2e9c2163e95689dae6b50ef8f9a10a5fb283a6c3aec39a350569c9- Stable URL of this page
https://metraipolis.com/documento/dc_a54b2dd9bf5f
How to cite
Patient-Reported Outcomes After Treatment With OnabotulinumtoxinA for Platysma Prominence: Results From a Phase 2 Dose-Ranging Study — Europe PMC PMID:41933889 — Europe PMC (en), https://europepmc.org/article/MED/41933889 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_a54b2dd9bf5f (Metraipolis archive dc_a54b2dd9bf5f, sha256 c0371134de2e9c2163e95689dae6b50ef8f9a10a5fb283a6c3aec39a350569c9)
BibTeX
@misc{dca54b2dd9bf5f,
title = {Patient-Reported Outcomes After Treatment With OnabotulinumtoxinA for Platysma Prominence: Results From a Phase 2 Dose-Ranging Study — Europe PMC PMID:41933889},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41933889},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_a54b2dd9bf5f; sha256 c0371134de2e9c2163e95689dae6b50ef8f9a10a5fb283a6c3aec39a350569c9},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41933889. Agents can read the archived copy with the MCP tool read_document.